Connecticut General Statutes/Title 21a/Chapter 417/Section 21a-70j

CGS § 21a-70j. Disclosures re legend drugs.

Each pharmaceutical marketing firm that employs or compensates a pharmaceutical representative who is engaged in marketing, promoting or providing information regarding a legend drug for human use in this state shall ensure that such pharmaceutical representative discloses, in writing, to a prescribing practitioner or pharmacist, each time such pharmaceutical representative makes contact with the prescribing practitioner or pharmacist:

(1) The list price of a legend drug when such pharmaceutical representative provides information concerning the legend drug to such prescribing practitioner or pharmacist based on the dose and quantity of such legend drug as described in the medication package insert; and

(2) Information on the variation efficacy of the legend drug marketed to different racial and ethnic groups, if such information is available.

Short History

(P.A. 23-171, S. 5; P.A. 24-80, S. 4.)

Long History

History: P.A. 24-80 substantially amended provisions including by transferring duties from pharmaceutical representative to pharmaceutical marketing firm, effective May 30, 2024.

PreviousCGS § 21a-70i. Registration of pharmaceutical manufacturer as pharmaceutical marketing firm. Fees. List of employees. Reports.NextCGS § 21a-70k. Authority of commissioner re pharmaceutical marketing firms. Regulations.